Evaluating the effects of allicin in COPD

Evaluating the effects of Allicin supplementation on clinical outcomes and quality of life in patients with Chronic Obstructive Pulmonary Disease (COPD)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240217061033N1

Enrollment

Registered

2024-10-27

Start date

2024-10-27

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease. Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention 1: Intervention group: The product is in the form of tablets with a dose of 500 mg of garlic (Allium sativum), which contains the active substance allicin at a concentration of 2-3 mg. Ea

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients diagnosed with Chronic Obstructive Pulmonary Disease according to GOLD guidelines (GOLD:The Global initiative for chronic Obstructive Lung Disease)

Exclusion criteria

Exclusion criteria: Patients who are in the period of exacerbation of the disease Patients who take anticoagulants Patients with immune system defects including HIV Patients with cancer/malignancy Patients who are allergic to medicine, Patients who need surgery Pregnant/ lactating women

Design outcomes

Primary

Measure	Time frame
Score of life quality based on ST GEORGE’S RESPIRATORY QUESTIONNAIR. Timepoint: The level of quality of life at the beginning of the study (before the start of the intervention) and 30 days after the start of consuming the product containing allicin. Method of measurement: ST GEORGE’S RESPIRATORY QUESTIONNAIRE (SGRQ). This questionnaire is organized in three parts. The first part includes pulmonary complaints in terms of sequence and severity (Symptoms), the second part includes activities that can lead to movement restriction and shortness of breath (Activity), and the third part includes the effects of social function and psychosocial disorders. Impact) is caused by a chronic respiratory disease that is measured in different dimensions. The scoring method of the St. George questionnaire is as a percentage from zero to 100. In such a way that for the patient who chooses the best mode among the options of a question, which indicates higher breathing quality, zero is considered and vice versa.;The degree of disability that breathlessness poses on day-to-day activities (degree of dyspnea) based on mMRC questionnaire (Modified Medical Research Council). Timepoint: The severity of dyspnea at the beginning of the study (before the start of the intervention) and 30 days after the start of consuming the product containing allicin. Method of measurement: The mMRC (Modified Medical Research Council) questionnaire ; a self-rating tool to measure the degree of dyspnea on a scale from 0 to 4.	—

Measure

Time frame

Score of life quality based on ST GEORGE’S RESPIRATORY QUESTIONNAIR. Timepoint: The level of quality of life at the beginning of the study (before the start of the intervention) and 30 days after the start of consuming the product containing allicin. Method of measurement: ST GEORGE’S RESPIRATORY QUESTIONNAIRE (SGRQ). This questionnaire is organized in three parts. The first part includes pulmonary complaints in terms of sequence and severity (Symptoms), the second part includes activities that can lead to movement restriction and shortness of breath (Activity), and the third part includes the effects of social function and psychosocial disorders. Impact) is caused by a chronic respiratory disease that is measured in different dimensions. The scoring method of the St. George questionnaire is as a percentage from zero to 100. In such a way that for the patient who chooses the best mode among the options of a question, which indicates higher breathing quality, zero is considered and vice versa.;The degree of disability that breathlessness poses on day-to-day activities (degree of dyspnea) based on mMRC questionnaire (Modified Medical Research Council). Timepoint: The severity of dyspnea at the beginning of the study (before the start of the intervention) and 30 days after the start of consuming the product containing allicin. Method of measurement: The mMRC (Modified Medical Research Council) questionnaire ; a self-rating tool to measure the degree of dyspnea on a scale from 0 to 4.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamin Iranikhah

Shahid Beheshti University of Medical Sciences

Saminiranikhah@sbmu.ac.ir+98 21 2641 2130

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026